AVXL

Insider Trades

Name	Value	Action	Price	Current Price
Donhauser Peter D.O.Director $10k2.8k shares BuyJun 14, 2024 $3.64 --

News

globenewswire.comAnavex Life Sciences Receives Expected Nasdaq Delinquency Notificationglobenewswire.comMay 22

globenewswire.comAnavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officerglobenewswire.comMay 6

globenewswire.comAnavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Diseaseglobenewswire.comApr 14

globenewswire.comAnavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conferenceglobenewswire.comApr 7

globenewswire.comAnavex Life Sciences Provides Comprehensive Regulatory Updateglobenewswire.comMar 30

Trade AVXL

About Anavex Life Sciences Corp.

Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.

CEO: Christopher U. Missling
IPO Date: Aug 2, 2006

Market Data

Open: $2.73
High: $2.78
Low: $2.59
Volume: 8.9M
Avg Volume: 1.5M
52W High: $13.99
52W Low: $2.41

Valuation

Market Cap: $253M
Enterprise Value: $121M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-39M
Revenue: $0
Net Income: $-46M
Cash: $103M
Debt: $0

Events

EarningsAug 11

EPS est. -0.08